top of page

SUBSCRIBE TO OUR NEWSLETTER

THE LATEST NEWS IN CANCER CLINICAL RESEARCH

AT MEDSIR WE ARE DEDICATED TO OFFER THE MOST RELEVANT NEWS ON THE LATEST ADVANCEMENTS IN ONCOLOGY CLINICAL RESEARCH. FIND OUT THE LATEST NEWS ON ONCOLOGY RESEARCH, REGULATORY APPROVALS, EVENTS, SCIENTIFIC CONFERENCES AND MUCH MORE!

DOWNLOAD COMPANY DOSSIER

Search

From Barcelona to Boston: MEDSIR Celebrates 13 Years Advancing Global Cancer Research Through Innovation and international Collaboration

From Barcelona to Boston: MEDSIR Celebrates 13 Years Advancing Global Cancer Research Through Innovation and international Collaboration

From Barcelona to Boston: MEDSIR Celebrates 13 Years Advancing Global Cancer Research Through Innovation and international Collaboration

Apr 222 min read

14 views

MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gileads Trodelvy® in Advanced Breast Cancer

MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gileads Trodelvy® in Advanced Breast Cancer

MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gileads Trodelvy® in Advanced Breast Cancer

Feb 264 min read

123 views

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

Dec 12, 20247 min read

193 views

MEDSIR showcases the DEMETHER Study: advancing therapeutic de-escalation and more effective treatments for advanced breast cancer

MEDSIR showcases the DEMETHER Study: advancing therapeutic de-escalation and more effective treatments for advanced breast cancer

MEDSIR showcases the DEMETHER Study: advancing therapeutic de-escalation and more effective treatments for advanced breast cancer

Dec 5, 20245 min read

192 views

MEDSIR takes part in the Nexus Conference to address the challenges and opportunities of geographic diversity in clinical trials

MEDSIR takes part in the Nexus Conference to address the challenges and opportunities of geographic diversity in clinical trials

MEDSIR takes part in the Nexus Conference to address the challenges and opportunities of geographic diversity in clinical trials

Oct 23, 20244 min read

163 views

Brain metastases: an oncological challenge requiring innovative solutions and multidisciplinary approaches

Brain metastases: an oncological challenge requiring innovative solutions and multidisciplinary approaches

Brain metastases: an oncological challenge requiring innovative solutions and multidisciplinary approaches

Sep 20, 20244 min read

133 views

MEDSIR presents new studies at ESMO that advance treatment of patients with poor prognosis cancers

MEDSIR presents new studies at ESMO that advance treatment of patients with poor prognosis cancers

MEDSIR presents new studies at ESMO that advance treatment of patients with poor prognosis cancers

Sep 16, 20245 min read

154 views

Experts ensure that early detection and proper prevention are key to tackling the future challenges of cancer

Experts ensure that early detection and proper prevention are key to tackling the future challenges of cancer

Experts ensure that early detection and proper prevention are key to tackling the future challenges of cancer

Sep 13, 20246 min read

41 views

MEDSIR’s PRIMED Study Shows Promising Results for Preventing Sacituzumab Govitecan related Side Effects in the Treatment of HER2-negative Advanced Breast Cancer

MEDSIR’s PRIMED Study Shows Promising Results for Preventing Sacituzumab Govitecan related Side Effects in the Treatment of HER2-negative Advanced Breast Cancer

MEDSIR’s PRIMED Study Shows Promising Results for Preventing Sacituzumab Govitecan related Side Effects in the Treatment of HER2-negative Advanced Breast Cancer

Jun 3, 20244 min read

198 views

MEDSIR, Debiopharm, initiate clinical collaboration to explore potential synergy of Debio 0123 & Sacituzumab Govitecan in advanced breast cancer

MEDSIR, Debiopharm, initiate clinical collaboration to explore potential synergy of Debio 0123 & Sacituzumab Govitecan in advanced breast cancer

MEDSIR, Debiopharm, initiate clinical collaboration to explore potential synergy of Debio 0123 & Sacituzumab Govitecan in advanced breast cancer

May 28, 20244 min read

312 views

MEDSIR Presents Two Translational Studies Focused on Biomarkers at AACR2024 Annual Meeting

MEDSIR Presents Two Translational Studies Focused on Biomarkers at AACR2024 Annual Meeting

MEDSIR Presents Two Translational Studies Focused on Biomarkers at AACR2024 Annual Meeting

Apr 9, 20243 min read

48 views

The Lancet publishes positive results from the PHERGain study in patients with localized HER2-positive breast cancer

The Lancet publishes positive results from the PHERGain study in patients with localized HER2-positive breast cancer

The Lancet publishes positive results from the PHERGain study in patients with localized HER2-positive breast cancer

Apr 4, 20243 min read

211 views

Press Release: DEBBRAH Cohort 5 and ATRACTIB trial at San Antonio Breast Cancer Symposium

Press Release: DEBBRAH Cohort 5 and ATRACTIB trial at San Antonio Breast Cancer Symposium

Press Release: DEBBRAH Cohort 5 and ATRACTIB trial at San Antonio Breast Cancer Symposium

Dec 8, 20235 min read

321 views

Press Release: PARSIFAL-LONG at San Antonio Breast Cancer Symposium

Press Release: PARSIFAL-LONG at San Antonio Breast Cancer Symposium

Press Release: PARSIFAL-LONG at San Antonio Breast Cancer Symposium

Dec 7, 20234 min read

559 views

Press Release: MiRaDor at San Antonio Breast Cancer Symposium

Press Release: MiRaDor at San Antonio Breast Cancer Symposium

Press Release: MiRaDor at San Antonio Breast Cancer Symposium

Dec 7, 20234 min read

154 views

MEDSIR presents the results of three new studies at ESMO 2023: LUPER, focusing on lung cancer

MEDSIR presents the results of three new studies at ESMO 2023: LUPER, focusing on lung cancer

MEDSIR presents the results of three new studies at ESMO 2023: LUPER, focusing on lung cancer

Oct 31, 20237 min read

134 views

Phergain Collaborators’ Ecosystem in Spain.

Phergain Collaborators’ Ecosystem in Spain.

Phergain Collaborators’ Ecosystem in Spain.

Jul 20, 20236 min read

102 views

MEDSIR at ASCO 2023

MEDSIR at ASCO 2023

MEDSIR at ASCO 2023

Jun 13, 202323 min read

223 views

PALMIRA Study at ASCO 2023

PALMIRA Study at ASCO 2023

PALMIRA Study at ASCO 2023

Jun 6, 20232 min read

193 views

PHERGain study at ASCO 2023

PHERGain study at ASCO 2023

PHERGain study at ASCO 2023

Jun 4, 20232 min read

167 views

bottom of page